Allergic rhinitis: therapeutic strategies update Lactococcus lactis Plasma and tranilast–roxithromycin combination
Main Article Content
Keywords
Allergic rhinitis, Tranilast, Roxithromycin, Lactococcus lactis Plasma
Abstract
* At present, there is no established definitive and reliable therapy for allergic rhinitis.
* Combined effects of tranilast, which inhibits mast cell degranulation, and a specific macrolide antibiotic, roxithromycin, which has T helper 2 (Th2) cell inhibitory effects through ligands and receptors, may aid significantly in managing allergic rhinitis.
* Lactococcus lactis strain Plasma (LC-Plasma) can induce plasmacytoid dendritic cells and consistent intake of LC-Plasma increases T helper 1 (Th1) responses, indicating a potential to suppress Th2 hypersensitivity conditions, such as allergic rhinitis.
* A novel treatment approach for hay fever can now be chosen based on to the severity of the disease and amount of scattered pollen.
References
2. Horiuchi Y. Usefulness of Lactococcus lactis strain Plasma for treatment of allergic rhinitis: Four case reports. Eur J Rhinol Allergy. 2023;6:69–71. 10.5152/ejra.2023.23093
3. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75:3069–76. 10.1111/all.14586
4. Horiuchi Y. Intractable prurigo nodularis: Synergistic effects of tranuilast and roxithromycin. Skinmed. 2022; 20:476–7.
5. Horiuchi Y. Seasonal facial erythema in a patient with allergic rhinitis treated using a combination of tranilast and roxithromycin. Immunopharmacol Immunotoxicol. 2023:45;508–10. 10.1080/08923973.2022.2151916
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.